RhumbLine Advisers’s Cullinan Oncology CGEM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $558K | Buy |
74,105
+2,767
| +4% | +$20.8K | ﹤0.01% | 2619 |
|
|
2025
Q1 | $540K | Buy |
71,338
+3,130
| +5% | +$23.7K | ﹤0.01% | 2530 |
|
|
2024
Q4 | $831K | Buy |
68,208
+5,348
| +9% | +$65.1K | ﹤0.01% | 2336 |
|
|
2024
Q3 | $1.05M | Buy |
62,860
+8,509
| +16% | +$142K | ﹤0.01% | 2243 |
|
|
2024
Q2 | $948K | Buy |
54,351
+7,649
| +16% | +$133K | ﹤0.01% | 2278 |
|
|
2024
Q1 | $796K | Buy |
46,702
+972
| +2% | +$16.6K | ﹤0.01% | 2386 |
|
|
2023
Q4 | $466K | Buy |
45,730
+491
| +1% | +$5K | ﹤0.01% | 2699 |
|
|
2023
Q3 | $409K | Sell |
45,239
-988
| -2% | -$8.94K | ﹤0.01% | 2732 |
|
|
2023
Q2 | $497K | Sell |
46,227
-4,866
| -10% | -$52.4K | ﹤0.01% | 2689 |
|
|
2023
Q1 | $523K | Buy |
51,093
+4,400
| +9% | +$45K | ﹤0.01% | 2411 |
|
|
2022
Q4 | $493K | Buy |
46,693
+911
| +2% | +$9.62K | ﹤0.01% | 2469 |
|
|
2022
Q3 | $587K | Buy |
45,782
+2,659
| +6% | +$34.1K | ﹤0.01% | 2422 |
|
|
2022
Q2 | $553K | Buy |
43,123
+11,078
| +35% | +$142K | ﹤0.01% | 2451 |
|
|
2022
Q1 | $336K | Buy |
32,045
+1,445
| +5% | +$15.2K | ﹤0.01% | 2600 |
|
|
2021
Q4 | $472K | Sell |
30,600
-425
| -1% | -$6.56K | ﹤0.01% | 2532 |
|
|
2021
Q3 | $700K | Buy |
31,025
+15,998
| +106% | +$361K | ﹤0.01% | 2394 |
|
|
2021
Q2 | $387K | Buy |
15,027
+3,443
| +30% | +$88.7K | ﹤0.01% | 2675 |
|
|
2021
Q1 | $483K | Buy |
+11,584
| New | +$483K | ﹤0.01% | 2515 |
|